KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Average: 2014-2025

Historic Equity Average for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $596.7 million.

  • Xenon Pharmaceuticals' Equity Average fell 27.31% to $596.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.7 million, marking a year-over-year decrease of 27.31%. This contributed to the annual value of $841.4 million for FY2024, which is 2.03% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Equity Average is $596.7 million, which was down 10.80% from $669.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Equity Average's 5-year high stood at $907.8 million during Q1 2024, with a 5-year trough of $223.8 million in Q1 2021.
  • Its 3-year average for Equity Average is $741.9 million, with a median of $729.4 million in 2025.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Equity Average skyrocketed by 204.18% in 2022 and then decreased by 27.31% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Equity Average (Quarterly) stood at $399.5 million in 2021, then spiked by 84.56% to $737.3 million in 2022, then climbed by 6.10% to $782.3 million in 2023, then declined by 0.75% to $776.4 million in 2024, then fell by 27.31% to $596.7 million in 2025.
  • Its Equity Average stands at $596.7 million for Q3 2025, versus $669.0 million for Q2 2025 and $729.4 million for Q1 2025.